Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
Asian cities are on the rise and are dominant in the Fintech space.Financeread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
The Pentagon on Thursday said the recent attack on Saudi Arabian oil facilities were "sophisticated" and represented a "dramatic escalation" in tensions within the region.Defenseread more
The flap illustrates the growing distrust of the YouTube community, and willingness to assume the worst in light of unclear communication.Technologyread more
Four years ago Microsoft had just two women on its board. Walmsley is now the fifth.Technologyread more
AT&T isn't focused on selling or divesting DirecTV, despite pressure from stakeholder Elliott Management, sources tell CNBC.Technologyread more
Generic drugmaker Mylan on Tuesday reported lower-than-expected fourth-quarter profit and forecast 2019 earnings well below Wall Street estimates, as it grapples with significant problems at its Morgantown, West Virginia, plant.
Mylan said the lower forecast was due to higher projected sales, marketing and research and development costs, and its shares fell about 10 percent.
Mylan Chief Executive Heather Bresch also said the company was still seeing pricing erosion in the U.S. generic market, but that new product launches should offset revenue decreases for existing products in 2019.
The company formed a review committee in August to evaluate possible strategic alternatives, citing the tough U.S. environment for generic drugmakers.
Bresch said she believes the committee is nearing completion of its review, and is considering anything and everything to increase value for shareholders.
Excluding one-time items, the company said it earned $1.30 per share, missing analysts' average expectations by 6 cents, according to IBES data from Refinitiv.
For 2019, the EpiPen maker forecast adjusted earnings of $3.80 to $4.80 a share and revenue of $11.5 billion to $12.5 billion. Analysts, on average were estimating earnings of $5.04 per share and sales of $11.9 billion.
Revenue for the quarter fell 5 percent to $3.08 billion.
Mylan received a warning letter from the U.S. Food and Drug Administration in November, flagging "significant" manufacturing violations at the Morgantown plant, including "inadequate" cleaning of equipment. The agency also said Mylan failed to thoroughly investigate batches of medicines that failed to meet specifications.
The company said fixing issues at the plant and layoffs that predate the warning letter hurt North American sales in the quarter.
Net earnings fell to $51.2 million, or 10 cents per share, in the quarter, from $244.3 million, or 46 cents per share, a year earlier.
Mylan's shares closed at $30.62 on the Nasdaq on Tuesday, but fell by about $3 in after-the-bell trading.